SCHEMBL3567550

SCHEMBL3567550

CSc1cccc(-c2c(F)cccc2Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
IDO1 P14902 1/20 0.40
TGFBR1 P36897 1/20 0.38
ALOX5 P09917 1/20 0.35
SYK P43405 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPK1 P28482 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
ALDH1A1 P00352 1/20 0.32
RAB9A P51151 1/20 0.32
CFTR P13569 1/20 0.32
KIF11 P52732 1/20 0.31
POLB P06746 2/20 0.31
MEN1 O00255 1/20 0.31
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
HSD17B10 Q99714 1/20 0.31
PTGS2 P35354 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3570882 0.80 IDO1 (0.40) AKR1C3AKR1C2IDO1TGFBR1SYK
SCHEMBL1865690 0.77 CSNK1E (0.43) AKR1C3AKR1C2L3MBTL1MAPK1SMN1; SMN2
SCHEMBL4302188 0.77 TAAR1 (0.42) IDO1MEN1TP53MAPTKMT2A
SCHEMBL22238791 0.75 CRHBP (0.39) MAPK1ALDH1A1MEN1KMT2A
SCHEMBL27277437 0.74 CYP1A2 (0.45) L3MBTL1MAPK1ALDH1A1MAPT
SCHEMBL3570521 0.74 CHRM1 (0.40) IDO1ALOX5L3MBTL1SMN1; SMN2RAB9A
SCHEMBL31232612 0.74 MAPK1 (0.52) AKR1C3AKR1C2IDO1L3MBTL1MAPK1
SCHEMBL2847105 0.73 DYRK1A (0.45) AKR1C3AKR1C2SMN1; SMN2RAB9AMEN1
SCHEMBL2847939 0.73 RXRA (0.41) L3MBTL1SMN1; SMN2ALDH1A1TP53MAPT
SCHEMBL2842712 0.73 BCL2 (0.41) IDO1TGFBR1KIF11TP53PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO claimed
US-7858624-B2 Piperidine and morpholine renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-12-28 US disclosed
US-20090275581-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2009-11-05 US disclosed
US-20090264428-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264432-A1 Piperidine and Morpholine Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
EP-2010488-A2 RENIN INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2009-01-07 EP disclosed
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO disclosed
WO-2007117559-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO disclosed
WO-2007117560-A2 PIPERIDINE AND MORPHOLINE RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275581-A1 RENIN INHIBITORS REN, ACE, SERPINB1 AKR1C3 1413/4885AKR1C2 1222/4885IDO1 2568/4885
US-20090264432-A1 Piperidine and Morpholine Renin Inhibitors REN, ACE, PREP AKR1C3 2276/4885AKR1C2 2005/4885IDO1 3328/4885
US-20090264428-A1 Renin Inhibitors REN, ACE, SERPINB1 AKR1C3 1316/4885AKR1C2 1054/4885IDO1 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.